Primary Objective:

To evaluate the effect of caplacizumab on prevention of recurrence of aTTP (proportion of participants with a recurrence of aTTP) during the overall study period.

Secondary Objectives:

• To evaluate effect of caplacizumab on

  • prevention of recurrence of TTP (the number of recurrences of TTP) during overall study period.
  • a composite endpoint consisting of aTTP-related mortality, recurrence of aTTP and major thromboembolic events during study drug treatment
  • restoring platelet counts as a measure of prevention of further microvascular thrombosis
  • refractory disease
  • biomarkers of organ damage: LDH, cardiac troponin I, serum creatinine
  • plasma exchange (PE) parameters (days of PE and volume of plasma used), days in intensive care unit, days in hospital
  • cognitive status of Japanese patients

• To evaluate safety profile of caplacizumab in Japanese patients

• To evaluate effect of caplacizumab on pharmacodynamic (PD) markers in Japanese patients

• To evaluate pharmacokinetic (PK) profile of caplacizumab in Japanese patients

• To evaluate immunogenicity of caplacizumab in Japanese patients

Study duration per participant is approximately 2 months up to approximately 6 months in case of treatment extension and recurrence during the study drug treatment period.

Inclusion criteria :

• Japanese participant must be 18 years or older at the time of signing the informed consent.
• Participants who have a clinical diagnosis of aTTP (initial or recurrent), which includes thrombocytopenia (defined as platelet count <100,000/µL), microangiopathic hemolytic anemia as evidenced by red blood cell fragmentation (eg, presence of schistocytes), and increased levels of LDH
• Participants who require initiation of daily PE treatment and have received a maximum of 1 PE treatment prior to enrollment in the study
• Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
• Capable of giving signed informed consent

Exclusion criteria:

• Platelet count ≥100,000/µL,
• Serum creatinine level > 2.3mg/dL in case platelet count is > 30,000µL
• Known other causes of thrombocytopenia
• Congenital TTP
• Clinically significant active bleeding or high risk of bleeding
• Malignant arterial hypertension
• Known chronic treatment with anticoagulant treatment that cannot be stopped
• Participants who were previously enrolled in a clinical study with caplacizumab and received caplacizumab or for whom the assigned treatment arm is unknown
• Participants currently or less than 28 days prior to enrollment in this study, enrolled in a clinical study with another investigational drug or device
• Clinical condition other than that associated with TTP, with life expectancy < 6 months, such as end-stage malignancy
• Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
• Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org